No Data
No Data
Express News | Novo's Weight-Loss Drug Wegovy Receives UK Nod For Heart Disease
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Novo Nordisk A/S - Share Repurchase Programme
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
No Data